07.14.23 -- Accelerate Development Timelines With Improved Characterization Methods

Following the successful outcomes delivered by CGTs, innovators must now make these modalities available at scale. Faster adoption of technologies will be vital to success and broad accessibility for patients. Review key areas of innovation that have the potential to reshape how these advanced therapeutics are manufactured at scale.

While AAV has proven to be a powerful tool, there are several challenges related to its development and manufacturing. LumaCyte’s Radiance® instrument has the potential to improve the characterization of cell-based AAV transfection and production, improving the efficiency and accuracy of both processes and shortening development time.

As allogeneic T-cell therapies move toward late-stage clinical trials and commercial registration, cell and gene therapy companies need to invest time, effort, and funds to improve process manufacturability. The manufacturing by design approach for addressing the industrialization of cell therapies allows for optimal production conditions.